Kornimate/medical-research-clean huggingface dataset:
extended spectrum beta lactamase producing organisms in urinary tract infections

Conditions: Urinary Tract Infections

Summary: urinary tract infection is among the most common nosocomial and community acquired infections. the information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy .resistance to antibiotic treatment in patients with urinary tract infections (utis) is a representative example of the increasing problem of antimicrobial resistance. extended-spectrum β-lactamases (esbls) has emerged as an important mechanism of resistance in gram-negative bacteria.

urinary tract infection is among the most common nosocomial and community acquired infections. the information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy . resistance to antibiotic treatment in patients with urinary tract infections (utis) is a representative example of the increasing problem of antimicrobial resistance. extended-spectrum β-lactamases (esbls) has emerged as an important mechanism of resistance in gram-negative bacteria. bacterial production of extended-spectrum β-lactamases (esbl) significantly reduces the efficacy of the most commonly used beta-lactam antibiotics for the empiric therapy of infections caused by putative gram-negative . extended spectrum beta-lactamase (esbl) is derived from the mutated beta-lactamase enzyme, beta-lactamase is an enzyme produced by bacteria that acts to inactivate beta-lactam class of antibiotics . extended spectrum beta-lactamase is most commonly produced by the enterobacteriaceae group, especially escherichia coli and klebsiella pneumonia. esbl-producing bacteria can also be resistant to the antibiotics class of aminoglycoside, fluoroquinolone, tetracycline, chloramphenicol, and sulfamethoxazole-trimethoprim. the presence of esbl-producing bacteria in an infection can result in treatment failure. antibiotic resistance causes a decrease in the effectiveness of treatment, increases transmission of infection, increases mortality, and increases the cost of health care, while the discovery of new antibiotics is getting less and less

Eligibility criteria:
inclusion criteria: * this study will be conducted on a group of patients who are diagnosed that have urinary tract infections exclusion criteria: * the cases that do not give bacterial growth .
impact of staphylococcus aureus on folliculitis decalvans

Conditions: Folliculitis Decalvans; Staphylococcus Aureus

Summary: the folliculitis decalvans (fd) is an orphan disease , common in consultation specialized on scalp. this disease is currently not curable, responsible for significant for patients. the pathophysiology is poorly understood, staphylococcus aureus (sa) appears to play a role, never previously studied, and the study will attempt to clarify it. controversies in the literature on the pathophysiological hypotheses can be summed up as follows : fd is it an infectious folliculitis where sa (almost always found on the lesions plays a direct role possibly aided by a lack of local immune protection , or is it a pustular inflammatory unknown cause where the sa has no direct role but is a cofactor or a simple germ superinfection. our study has plans to bring new evidence to help decide between these two opposite but not mutually exclusive concepts .


Eligibility criteria:
inclusion criteria: * adult (\>18 yo) * alopecia * folliculitis decalvans * at least 6 months of evolution * no antibiotics * presence of pustules and crusts * adult (\>18 yo) exclusion criteria: * immunosuppression * pregnancy

Keywords: folliculitis decalvans staphylococcus aureus antibiotics
hyperthermy endocavitary treatment in pelvic pain

Conditions: Pelvic Pain

Summary: * treatment at pelvic floor with hyperactivity with hyperthermy electrode mjs * mjs electrode is effective for transvaginal treatment at pelvic pain patients * hyperthermy treatment with mjs electrode is more effective to usual drugs treatment

this study analyzed the evolution of chronic pelvic pain, defined by the different map of myofascial trigger points assets presents the patient with medical treatment compared to treatment with radiofrequency endocavitary electrode mjs. the initial evaluator analyzed by the nih-cpsi scale questionnaire and symptoms of chronic pelvic pain stanford protocol for female or male quality of life of the patient before the doctor or radio frequency and a month since treatment. the patient to the principal investigator, specialist physiotherapist, who appreciates tenderness the presence of a taut band with a map of pain in endopelvic and exopelvic muscles, determining the activation of myofascial trigger points in each is derived. the principal investigator proceeds to address each active myofascial trigger points with the mjs electrode four 20-minute sessions twice a week. the mjs has a curved end pressure which favors the compression point plus the location and accurate approach radiofrequency pathological point as outstanding feature. the high specificity of myofascial treatment offered by the mjs electrode involves no danger, besides having the computer screen conductivity meter and a temperature sensor on the head to control both parameters in real time during the treatment session

Eligibility criteria:
inclusion criteria: * women with chronic pelvic pain exclusion criteria: * chronic pelvic pain or neurological degenerative etiology * presence of pathology or infectious processes genitourinary level * possibility of pregnancy or lactating. * lack of informed consent, mental disorders, dementia, dependent people who need tutor.

Keywords: chronic pelvic pain trigger points hiperthermy
eras in elderly colorectal cancer surgery

Conditions: ERAS; Colo-rectal Cancer; Elderly (people Aged 65 or More); Minimally Invasive Surgery

Summary: enhanced recovery protocol consisted of a series of elements aiming to optimize and standardize perioperative care. this study aims to evaluate the safety and feasibility of a modified eras protocol following colorectal surgery in the elderly population, aged 65 years or older. this is a retrospective study based on prospectively collected data. patient privacy has been carefully protected throughout the research process, and no aspect of this study interfered with or altered the patients' treatment or clinical care.


Eligibility criteria:
inclusion criteria: * they underwent radical resection for colorectal cancer * the procedure was minimally invasive surgery * they were aged 65 or older * they provided signed informed consent. exclusion criteria: * patients who underwent emergency surgery for colorectal cancer. * patients with incomplete medical records or missing data relevant to the study. * patients with synchronous malignancies or a history of other cancers within the past five years. * patients with severe comorbidities (e.g., advanced cardiovascular, respiratory, or renal diseases) that contraindicate eras protocol implementation. * patients with preoperative metastatic disease or locally advanced tumors requiring palliative procedures. * patients who did not comply with or complete the eras protocol during the perioperative period.
inverted ilm repositioning as treatment for full thickness macular holes

Conditions: Macular Holes

Summary: the purpose of this study is to evaluate the efficacy and safety of surgical treatment of ftmh using an inverted ilm repositioning to improve anatomical and functional outcomes in patients with a macular hole.

at present, the anatomical closure rate of macular hole is around 90% using pars plana vitrectomy with ilm peeling. improvement of visual acuity is around 80% including stage ii to iv. with macular hole greater than 400 μm there is higher risk of surgical failure and visual acuity is usually less than 0.2. large macular holes are more likely to have flat-open type closure, which is anatomical success but has limited improvement in visual acuity. inverted ilm repositioning will form a scaffold for glial cells, which allows their migration and proliferation. this process will close the macular hole and secure it from re-opening, and will reduce the risk of flat-open type of closure. the aim of this study is to estimate the efficiency and safety of inverted ilm repositioning in the treatment of macular hole with a minimum diameter exceeding 400 μm and compare results with the currently used methods of surgical large macular holes treatment.

Eligibility criteria:
inclusion criteria: * full-thickness macular hole with a minimum diameter exceeding 400 μm * bcva of 0,3 or worse in log mar units (\ =5 etrds letter) * 18 years of age * informed consent exclusion criteria: * eyes with previous vitreous surgery * cystoid macular edema from any cause * post traumatic macular hole * macular hole associated with retinal detachment * any other ocular reason which causes the lack of improvement after macular hole surgery (e.g pigmentary abnormalities, age-related macular degeneration, corneal scarring)

Keywords: ftmh ppv inverted ilm repositioning
effect of ginkgo biloba extract on cognitive function in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.

vascular brain injury is a common post-stroke complication that can reduce cognitive function and lead to vascular cognitive impairment, placing a significant burden on families and society. the purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.

Eligibility criteria:
inclusion criteria: 1. patients with a definitive clinical diagnosis of acute ischemic stroke; 2. age≥18 years, regardless of sex； 3. primary education level or higher; baseline moca score of 10-25 points; 4. able to complete cognitive scale scoring; 5. informed consent is signed and ginkgo biloba extract therapy is initiated within 14 days of onset. exclusion criteria: 1. transient ischemic attack； 2. patients who received emergency reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy) at onset; 3. combined with other neurological diseases, such as neurodegenerative diseases (e.g., alzheimer's disease, parkinson's disease, lewy body dementia, and frontotemporal dementia), optic neuritis, epilepsy, central nervous system infections (e.g., aids and syphilis), traumatic brain injury dementia, etc； 4. currently using psychoactive medications (e.g., antidepressants) or anti-epileptic drugs, or if the time since their last use of these medications was less than 5 half-lives (per the pharmacokinetics of each specific medication; for drugs with unknown half-lives, a 1 month washout period was required)； 5. had a pre-existing diagnosis of a cognitive disorder； 6. currently taking medications intended to improve cognitive function or prevent dementia (e.g., cholinesterase inhibitors, memantine, nootropics), or if the washout period since their last use of these medications was less than 5 half-lives as specified in each drug's pharmacokinetics. for drugs with unknown half-lives, a minimum 1 month washout period was required； 7. severe liver and kidney dysfunction; 8. active ulcer or bleeding diathesis； 9. allergy to preparations containing ginkgo biloba extract； 10. pregnant or lactating women, patients with a life expectancy less than 6 months, and those unable to complete the study for other reason； 11. unwillingness to be followed up or poor treatment compliance; 12. those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment; 13. other conditions that the investigators deemed unsuitable for enrollment.
optimal passive dilation time in retrograde intrarenal surgery

Conditions: Stone, Kidney; Urolithiasis

Summary: retrograde intrarenal surgery (rirc) is used as standard treatment for stones less than 2 cm. in some cases, the ureteral access sheath cannot be placed due to ureteral stricture. in this case, a double j stent (dj) is placed to passively dilate the ureter, and the rirc is postponed for post-dilatation. the aim of the study is to determine the optimal time for rirc operation in cases where a double j stent was placed for passive dilatation.


Eligibility criteria:
inclusion criteria: * patients with a dj stent for passive dilatation and subsequent rirc exclusion criteria: * urinary tract infection, patients with ureteral compression and a history of pelvic radiotherapy, urinary system tumor
efficacy and safety of ciclesonide (cic) administered twice daily in pediatric patients with asthma.

Conditions: Asthma

Summary: primary objective: to demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (bid) or 40 μg bid for 12 weeks in patients with persistent asthma. secondary objective: to assess the safety and tolerability of ciclesonide.


Eligibility criteria:
inclusion criteria: * history of persistent bronchial asthma for at least 3 months prior to screening; * for patients with persistent bronchial asthma and being treated with a controller therapy: documented use of an inhaled steroid or singulair® 5mg once daily; * for patients with persistent bronchial asthma and not being treated with controller therapy: patients may have documented use of a reliever therapy such as albuterol/salbutamol or may be untreated; * morning peak expiratory flow (am pef) of ≤90% of predicted values from the in-clinic spirometry after a 6 hour withhold of albuterol/salbutamol; * only patients aged between 6 to \<12 years must have a forced expiratory volume in one second (fev1) of ≥50% to ≤85% of predicted normal after a 6 hour withhold of albuterol/salbutamol exclusion criteria: * nocturnal awakenings for asthma which require treatment with albuterol/salbutamol for 4 or more nights out of the last 7 days of the screening period; * use of more than 8 puffs/day of albuterol/salbutamol on 3 or more consecutive days within the last 7 * upper or lower respiratory tract infection within 4 weeks prior to screening and during screening period; * history of life-threatening asthma, including a history of significant hypercarbia (pco2 \>45 mmhg), prior intubation, respiratory arrest, or seizures as a result of an exacerbation of asthma; * more than 3 in-patient hospitalization or emergency care visits due to asthma exacerbations in the year prior to screening; * use of injectable or oral corticosteroids within one month prior to screening, or more than 3 bursts) within 6 months prior to screening;

Keywords: bronchial asthma
researching heat and yoga for mood enhancement

Conditions: Depression

Summary: this study will examine how doing heated yoga or non-heated yoga affects depression.

the purpose of this study is to investigate the effects of heated and non-heated yoga on depressive symptoms. previous research trials using heated and non-heated yoga interventions have shown promising results for reducing depression and its related outcomes. however, no studies have directly compared the effects of heated vs. non-heated yoga for depression. the researchers aim to address this gap by conducting a non-inferiority trial comparing heated yoga and non-heated yoga interventions to improve depressive symptoms. both the heated and non-heated yoga interventions will be conducted in-person by certified yoga instructors. eligible participants will be adults who do not regularly practice yoga or meditation and are experiencing moderate levels of depression. assessments will be conducted at baseline, mid-treatment, post-treatment, and follow-up using a secure data capture system.

Eligibility criteria:
inclusion criteria: 1. adults (18-65 years old) 2. able to provide consent 3. are able to read and understand english 4. phq-9 score between 10-20, indicating moderate but not severe depressive symptom severity (27) 5. must have filled out the waiver for the community-based yoga studio prior to enrolling in the study. exclusion criteria: 1. have had a bone fracture or joint surgery in the past 6 months 2. not able to walk freely or without difficulty 3. have severe heart failure or lung disease 4. participants endorse an item on the revised physical activity readiness questionnaire (par-q+) and do not have approval from their treating physician (we will check in with treating physician in the event that participants endorse any item on the par-q+) 5. participants must have a physician responsible for their medical care 6. are pregnant or planning to become pregnant 7. no more than 6 yoga classes in the past 6 months 8. have active suicidal thinking (i.e., phq-9 item 9 ≥1 and a positive response to c-ssrs screener items 3, 4, 5, or 6) 9. report manic symptoms (altman self-rating mania scale score ≥ 6 (28)) 10. are on medications that make dehydration more likely (e.g., lithium, antipsychotics, insulin-dependent) 11. active eating disorders or substance use disorders within the past 12 months 12. antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit 13. psychotherapy that has been initiated within the past 3 months 14. willingness to keep psychiatric medications and psychotherapy stable throughout the course of the study 15. psychiatric hospitalization within the past year 16. diagnosed with any neurological disorders that would impact participation or make participation unsafe 17. are currently in any active ketamine, ect, or tms 18. are unable to follow the study procedures (e.g., not able to travel to the heated or non-heated yoga studios)
active vitamin d and reduced dose prednisolone for treatment in minimal change nephropathy

Conditions: Minimal Change Disease; Nephrotic Syndrome

Summary: traditionally mcn is treated with a high dose of prednisolone, which induces remission in 60-90% of patients. prednisolone treatment contains numerous side effects and the current dose is empiric. given the lack of efficacy evidence and the risk associated with the currently accepted treatment regimen there is a need to characterize the outcome in mcn further, and to establish new, and potentially less toxic treatment regimens. the aim is to examine if treatment with reduced dose of prednisolone in combination with activated vitamin d is as effective as standard high dose prednisolone in achieving remission and preventing relapse in mcn, and if reduced dose prednisolone is associated with fewer side effects compared to standard dose. furthermore, the study will examine the influence of prednisolone metabolism on the efficacy and side effects of prednisolone in the treatment of mcn.


Eligibility criteria:
inclusion criteria: * biopsy proven minimal change nephropathy * if earlier minimal change: no relapse in 5 years, and earlier only treated with prednisolone * nephrotic syndrome * age more than 18 years exclusion criteria: * cancer except from basal cells carcinoma * lymphoproliferative disease * pregnancy * egfr \< 30 ml/min/1,73m2 (ckd-epi) * allergy * no danish language * no ability to give informed prove

Keywords: prednisolone alfacalcidol minimal change nephropathy
physical activity in overweight girls: implications for reversing risk factors for type 2 diabetes

Conditions: Abdominal Obesity; Physical Activity

Summary: in this randomized controlled trial, we will examine the effect of a 3-month exercise training (aerobic exercise versus resistance exercise) without calorie restriction on total and regional adiposity, ectopic fat in the liver and skeletal muscle, and risk of type 2 diabetes in overweight girls.


Eligibility criteria:
inclusion criteria: * healthy overweight (bmi \>-95th) youth between 12 and 18 years of age * waist circumference \>-75th percentile * sedentary (no structured exercise \>2 times/week for past 6 months) * non-smokers, non-diabetic, no medical conditions * weight stable for past 3 months exclusion criteria: * smokers * diabetes * psychiatric disorders * syndromic obesity * pregnancy * taking medications known to affect study outcomes

Keywords: childhood obesity visceral fat insulin resistance liver fat skeletal muscle lipid regular exercise
a study of multiple doses of ro7247669 in participants with previously untreated unresectable or metastatic melanoma

Conditions: Melanoma

Summary: the purpose of this study is to assess the efficacy, safety, pharmacokinetics (pk), and pharmacodynamics of two dose levels of ro7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.


Eligibility criteria:
inclusion criteria: * histologically confirmed unresectable or metastatic melanoma, per the american joint committee on cancer (ajcc) staging system (unresectable stage iii or stage iv) * radiologically measurable disease according to response evaluation criteria in solid tumors (recist) v1.1 * eastern cooperative oncology group (ecog) performance status 0-1 * known v-raf murine sarcoma viral oncogene homolog b1 (braf) v600 mutation status * adequate cardiovascular, hematological, hepatic and renal function * willingness to abide by contraceptive measures for the duration of the study * participants must have known pd-l1 status exclusion criteria: * pregnancy, lactation, or breastfeeding * known hypersensitivity to any of the components of ro7247669 * participants must not have ocular melanoma * symptomatic central nervous system (cns) metastases * significant cardiovascular/cerebrovascular disease within 6 months prior to randomization * known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with intravenous (iv) antibiotics or hospitalization within 28 days prior to randomization * major surgical procedure or significant traumatic injury (excluding biopsies) within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study * active or history of autoimmune disease or immune deficiency with some exceptions * prior systemic anticancer therapy for unresectable or metastatic melanoma * prior anticancer therapy with any-immunomodulatory agents including cpis (such as anti-programmed death-ligand 1\[pd-l1\]/pd-1 and anti-cytotoxic t lymphocyte-associated antigen \[ctla-4\]) with some exceptions if used as prior adjuvant or neoadjuvant melanoma therapies * prior treatment with anti-lag3 therapy
oxidative stress in critical ill patients in surgical intensive care unit

Conditions: Sepsis; Shock

Summary: in clinical practice, the oxidative stress is related to circulatory shock, sepsis, acute lung injury, and acute respiratory distress syndrome. there are some questions on the oxidative stress of the critical illness. first, the investigators want to search out the effects of the past history, smoking, alcohol drinking, use of antioxidants, different diseases, and different duration of sirs on the degree of oxidative stress. second, besides total count of ros, the investigators used new techniques to determine superoxide(o2●-), hydrogen peroxide (h2o2), and hypochlorous acid(hocl). furthermore, we want to investigate the correlation of the degree of different reactive oxygen species and the severity of sirs or shock. third, we try to investigate the correlation between the change of oxidative stress and the prognosis of the patients. the investigators wish this study will help them to investigate the effect of oxidative stress on critical ill patients, to modulate the oxidative stress, to decrease the occurrence of sirs, shock, and multiorgan failure, and to improve the long term outcome of patients.


Eligibility criteria:
inclusion criteria: * age \> 18 y/o * admitted to surgical icu exclusion criteria: * patients with brain death

Keywords: oxidative stress intensive care postoperative intensive care